** GSK just got the green light in Japan to use its blood-cancer treatments in combination therapies. This comes after promising Phase 3 trial results, and the company is optimistic about further approvals later this year.

What This Mean: ** For patients battling blood cancers, this could mean more effective treatment options on the horizon. Japan’s approval signals confidence in GSK’s approach, and if other regions follow suit, it could expand access globally. It’s also a big win for GSK—more approvals could strengthen its position in the competitive cancer drug market.